vs
Side-by-side financial comparison of NexPoint Residential Trust, Inc. (NXRT) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
NexPoint Residential Trust, Inc. is the larger business by last-quarter revenue ($62.1M vs $57.3M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -2.7%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -4.1%).
NexPoint Residential Trust, Inc. is a publicly traded real estate investment trust focused on acquiring, renovating, and operating multifamily residential properties primarily across high-growth Sun Belt markets in the United States. Its portfolio consists mainly of affordable and mid-tier apartment communities, targeting steady rental income growth and long-term asset value appreciation for investors.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
NXRT vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $57.3M |
| Net Profit | — | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 8.4% | -82.2% |
| Net Margin | — | -83.0% |
| Revenue YoY | -2.7% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | — | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $57.3M | ||
| Q3 25 | $62.8M | $51.3M | ||
| Q2 25 | $63.1M | $48.5M | ||
| Q1 25 | $63.2M | $32.7M | ||
| Q4 24 | $63.8M | $41.8M | ||
| Q3 24 | $64.1M | $33.3M | ||
| Q2 24 | $64.2M | $29.1M | ||
| Q1 24 | $67.6M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-7.8M | $-52.9M | ||
| Q2 25 | $-7.0M | $-46.6M | ||
| Q1 25 | $-6.9M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-8.9M | $-43.6M | ||
| Q2 24 | $10.6M | $-32.3M | ||
| Q1 24 | $26.3M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 8.4% | -82.2% | ||
| Q3 25 | 11.8% | -102.6% | ||
| Q2 25 | 12.5% | -93.4% | ||
| Q1 25 | 11.7% | -143.7% | ||
| Q4 24 | 18.0% | -98.6% | ||
| Q3 24 | 8.7% | -132.0% | ||
| Q2 24 | 39.7% | -139.2% | ||
| Q1 24 | 60.7% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | -12.4% | -103.1% | ||
| Q2 25 | -11.1% | -96.1% | ||
| Q1 25 | -10.9% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -13.8% | -131.2% | ||
| Q2 24 | 16.5% | -110.9% | ||
| Q1 24 | 38.9% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | $-0.31 | $-0.82 | ||
| Q2 25 | $-0.28 | $-0.75 | ||
| Q1 25 | $-0.27 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $-0.35 | $-0.73 | ||
| Q2 24 | $0.40 | $-0.55 | ||
| Q1 24 | $1.00 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $388.9M |
| Total DebtLower is stronger | $1.6B | — |
| Stockholders' EquityBook value | $295.5M | $139.1M |
| Total Assets | $1.9B | $480.2M |
| Debt / EquityLower = less leverage | 5.39× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | $388.9M | ||
| Q3 25 | $10.8M | $416.1M | ||
| Q2 25 | $13.6M | $291.0M | ||
| Q1 25 | $23.7M | $314.5M | ||
| Q4 24 | $23.1M | $320.6M | ||
| Q3 24 | $17.4M | $298.4M | ||
| Q2 24 | $21.3M | $319.1M | ||
| Q1 24 | $37.2M | $201.2M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $295.5M | $139.1M | ||
| Q3 25 | $322.9M | $148.8M | ||
| Q2 25 | $347.9M | $-11.9M | ||
| Q1 25 | $379.9M | $18.9M | ||
| Q4 24 | $410.4M | $21.7M | ||
| Q3 24 | $447.1M | $11.2M | ||
| Q2 24 | $491.1M | $39.3M | ||
| Q1 24 | $512.8M | $61.6M |
| Q4 25 | $1.9B | $480.2M | ||
| Q3 25 | $1.8B | $506.9M | ||
| Q2 25 | $1.9B | $372.7M | ||
| Q1 25 | $1.9B | $386.7M | ||
| Q4 24 | $1.9B | $392.3M | ||
| Q3 24 | $2.0B | $363.6M | ||
| Q2 24 | $2.0B | $381.8M | ||
| Q1 24 | $2.0B | $258.7M |
| Q4 25 | 5.39× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.92× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.6M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.6M | $-25.4M | ||
| Q3 25 | $29.3M | $-26.6M | ||
| Q2 25 | $19.9M | $-23.3M | ||
| Q1 25 | $28.3M | $-40.4M | ||
| Q4 24 | $73.6M | $-18.8M | ||
| Q3 24 | $27.8M | $-25.2M | ||
| Q2 24 | $19.7M | $-29.1M | ||
| Q1 24 | $19.7M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
